Dopamine D1 receptors labelled with [3H]SCH23390 in rabbit cerebral cortex and neostriatum. Equilibrium binding, kinetics and selectivity

Drugs, biogenic amine targets and the developing brain

Defects in the development of the brain have a profound impact on mature brain functions and underlying psychopathology. Classical neurotransmitters and neuromodulators, such as dopamine, serotonin, norepinephrine, acetylcholine, glutamate and GABA, have pleiotropic effects during brain development. In other words, these molecules produce multiple diverse effects to serve as regulators of distinct cellular functions at different times in neurodevelopment. These systems are impacted upon by abuse of a variety of illicit drugs, neurotherapeutics and environmental contaminants. In this review, we describe the impact of drugs and chemicals on brain formation and function in animal models and in human populations, highlighting sensitive periods and effects that may not emerge until later in life.

Prenatal exposure to cocaine produces unique developmental and long-term adaptive changes in dopamine D1 receptor activity and subcellular distribution

Low-dose intravenous cocaine administration to pregnant rabbits causes permanent structural alterations in dopamine-rich cerebral cortical areas, substantially reduced dopamine D1 receptor coupling to G(s)-protein, and deficits in cognitive function. The developmental influences of reduced D1-G(s) coupling and the underlying cellular basis are unknown. Using primary neuronal cultures derived from the medial frontal cortex and striatum of in utero saline- and cocaine-exposed embryos, spontaneous neurite outgrowth of in utero-exposed cortical neurons was greater than in control neurons. In contrast, striatal neurons exposed to cocaine in utero exhibited an entirely opposite adaptive response, with diminished spontaneous neurite outgrowth compared with saline-exposed controls. Control neurons isolated from the two structures also exhibited opposite regulatory responses to the D1 receptor agonist SKF38393 (1-phenyl-2,3,4-5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride), inhibiting outgrowth in cortical cultures and stimulating outgrowth in striatal cultures. The agonist was ineffective in modulating neurite outgrowth of neurons from either structure isolated from cocaine-exposed fetuses, reflecting the reduced D1-Gs coupling. Total D1 receptor number was indistinguishable in neurons from the cocaine- and saline-exposed animals, but cell imaging and receptor binding of differentially isolated membranes showed that the lack of responsiveness was because of greatly reduced cell-surface localization of D1 receptors. These data suggest that prenatal exposure to cocaine causes a novel, long-lasting adaptive response in the subcellular distribution of D1 receptors, resulting in alterations in signaling capacity that have developmental and behavioral consequences.

Effects of chronic ethanol treatment and ethanol withdrawal on [3H]SCH23390 binding to rat striatal membranes

The effects of chronic ethanol administration and ethanol withdrawal on the kinetic and pharmacological properties of [3H]SCH23390 binding sites and the labelling of central dopamine D-1 receptors were studied in the striatum of the rat. Chronic 40 day ethanol treatment produced a statistically significant decrease (p < 0.05) in maximum binding (Bmax) on striatal dopamine D-1 receptors of the rat, KD remaining unaltered. The withdrawal of ethanol did not affect the kinetic binding parameters. The rank order of potency in displacing the specific [3H]SCH23390 binding of several dopamine antagonists, agonists and serotonin-related drugs was consistent with the pharmacological profile of dopamine D-1 receptors. Chronic ethanol treatment led to a statistically significant increase in receptor affinity (lower Ki than controls) for (+)-butaclamol (p < 0.05). Ethanol withdrawal for 24 hr increased the affinity of [3H]SCH23390-labeled binding sites for norepinephrine. The addition of 0.03-0.68 M ethanol in vitro had no significant effects on [3H]SCH23390 binding in striatal preparations taken from both control and ethanol-treated rats. The results show that rat striatal [3H]SCH23390-labelled binding sites are affected by different conditions of ethanol exposure, possibly suggesting the medication of striatal dopamine pathways in the responses to ethanol intoxication.

Characterisation of dopamine receptors in insect (Apis mellifera) brain

In vitro binding experiments using the vertebrate D1 dopamine receptor ligand [3H]SCH23390 and the vertebrate D2 dopamine receptor ligand [3H]spiperone were conducted on membrane preparations of honey bee (Apis mellifera) brain. Specific binding of [3H]SCH23390 was saturable and reversible. Analysis of saturation data gave an apparent Kd of 6.3 +/- 1.0 nM and Bmax of 1.9 +/- 0.2 pmol/mg protein for a single class of binding sites. The specificity of high affinity [3H]SCH23390 binding was confirmed in displacement experiments using a range of dopaminergic antagonists and agonists. The rank order of potency for antagonists was: R(+)-SCH23390 > cis-(Z)-flupentixol > or = chlorpromazine > fluphenazine > S(+)-butaclamol > spiperone. R(+/-)-SKF38393 and dopamine were the most effective agonists tested. [3H]SCH23390 labels a site in bee brain that is similar, but not identical to the vertebrate D1 dopamine receptor subtype. [3H]Spiperone also bound with high affinity to bee brain homogenates. Scatchard analysis of [3H]spiperone saturation data revealed a curvilinear plot suggesting binding site heterogeneity. The high affinity site had a apparent Kd of 0.11 +/- 0.02 nM and Bmax of 9.2 +/- 0.5 fmol/mg protein. The calculated values for the low affinity site were a Kd of 19.9 nM and Bmax of 862 fmol/mg protein. Kinetic analyses also indicated that [3H]spiperone recognises a heterogeneous population of sites in bee brain. Furthermore, agonist competition studies revealed a phenolaminergic as well as a dopaminergic component to [3H]spiperone binding in bee brain. The rank order of potency of dopaminergic antagonists in competing for [3H]spiperone binding was: spiperone > fluphenazine > S(+)-butaclamol > domperidone > R(+)-SCH23390 > S(-)-sulpiride.

Comparative biochemical pharmacology of central nervous system dopamine D1 and D2 receptors

The biochemical properties of central nervous system (CNS) dopamine (DA) D1 and D2 receptors were examined using the specific antagonists [3H]SCH23390 and [3H]raclopride, respectively. There is a different participation of sulfhydryl (-SH) and disulfide (-SS-) groups in the binding site and/or coupling to second messenger systems of D1 and D2 receptors. The ionic studies with [3H]SCH23390 showed slight agonist and antagonist affinity shifts for the D1 receptor. On the other hand, the D2 receptor is very sensitive to cations; even if lithium and sodium influence specific [3H]raclopride binding in a similar manner, there appear to be quantitative differences between these two ions that cannot be explained by surface charge mechanisms. The distribution of D1 and D2 receptors was heterogenous in both species, with the greatest densities in the neostriatum, where the highest concentrations of DA and metabolites were measured. Regions with low endogenous DA content (cerebral cortex and hippocampus) had lower densities of DA receptors. Furthermore, these binding sites were differentially localized within the various regions, and there were substantially more D1 than D2 receptors. The functional significance and heterogeneities in the distribution of D1 and D2 receptors can be related to dopaminergic innervation and turnover.